Cardiac release and kinetics of cytokines after elective bare metal coronary stenting

NourEddine ElMokhtari1, Sascha Zschernitz, Susanne Sebens

  • 1Department of Cardiology, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 12, Kiel 24105, Germany.

Insights

Percutaneous coronary intervention (PCI) causes cardiac release of interleukin-6 (IL-6) due to endothelial injury, not myocardial ischemia. This finding is crucial for understanding post-PCI inflammation and recovery.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Interventional Cardiology

Background:

  • Cytokine release following cardiovascular procedures is not fully understood.
  • Interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and tumor-necrosis-factor-α (TNF-α) are key inflammatory mediators.
  • Assessing cytokine kinetics after coronary interventions is important for patient outcomes.

Purpose of the Study:

  • To evaluate the cardiac release kinetics of IL-1ß, IL-6, and TNF-α after bare metal stent implantation.
  • To differentiate between cytokine release due to myocardial ischemia versus endothelial injury post-PCI.
  • To compare cytokine levels in patients undergoing PCI with a control group.

Main Methods:

  • Prospective study comparing 10 patients with coronary intervention to 11 controls.
  • Measurement of IL-1ß, IL-6, and TNF-α in coronary sinus and peripheral blood samples.
  • Monitoring of myocardial ischemia using lactate metabolism and ECG.

Main Results:

  • A significant increase in IL-6 was observed post-PCI, peaking at 6 hours.
  • Higher IL-6 levels in the coronary sinus compared to peripheral veins indicated cardiac IL-6 release.
  • No significant changes in IL-1ß or TNF-α were found in either group; myocardial ischemia was excluded.

Conclusions:

  • Uncomplicated percutaneous coronary intervention (PCI) leads to significant cardiac release of IL-6.
  • The observed IL-6 release is attributed to endothelial injury, not myocardial ischemia.
  • These findings highlight the inflammatory response post-PCI and guide further research into managing post-procedural inflammation.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...